News and research before you hear about it on CNBC and others. Request your weeklong free trial to StreetInsider Premium here.
NEWCASTLE UPON TYNE, UK, 26th NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”) today confirms that both its SARS-CoV-2 assays for open PCR platforms and its high-speed PCR device Q-POC ™ and its future airway panel (SARS-CoV-2, Flu A, Flu B and RSV A / B) can still detect all known virus strains, including the latest variant B.1.1.529.
In silico The analysis of the mutations shown in the genome sequences of the variant that are publicly available in GISAID (the online database for SARS-CoV-2 genome sequences) shows that none of the primer or probe sites are affected by the mutations. This is testament to the advanced assay design of the QuantuMDx and underscores the quality of the company’s products.
Jonathan O’Halloran, Chief Executive, QuantuMDx, said, “After discovering this new variant, we performed a detailed mutation analysis to fully assess the reliability of our existing tests and Q-POC ™.
“Our assay design strategy of including three targets, most of which target only one or two regions of the SARS-CoV-2 genome, has proven robust, and with all of the new variations we are confident that our tests and The device can still recognize all known variants. “
QuantuMDx is a company passionate about empowering the world to control disease and alleviate suffering. QuantuMDx tackles real-world diagnostic problems by providing molecular point-of-care solutions for anyone, anywhere.
Q-POC ™ is a fast, easy-to-use, portable PCR device with probe response and is designed for use in a wide variety of environments such as hospitals, clinics, pharmacies and workplace tests that need accurate PCR results. Q-POC ™ and its first test, a SARS-CoV-2 detection assay, are CE-IVD-marked in accordance with the In Vitro Diagnostic Directive (98/79 / EC) and enable use in Europe
Notes to the editors:
QuantuMDx has offices and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics.
In scientific experiments and research “in silico” tests that are carried out or created using computer modeling or computer simulation.
Jonathan O’Halloran, Chief Executive, QuantuMDx, is available for interviews on the topic of the new Covid variant B.1.1.529 and the importance of PCR tests.
For media inquiries and interview requests:
Emma Long, Marketing Communications Manager, QuantuMDx, M: +44 (0) 7495 341 930 T: +44 (0) 870 803 1234 E: [email protected]
Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, +44 (0) 20 3709 5700 / [email protected]
For investor inquiries:
David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Advisor to QuantuMDx), +44 (0) 20 3705 9330 / [email protected]